<div class="docx-content">
<h1 class="text-2xl font-bold mt-8 mb-4"><strong>Brucella</strong></h1><h2 class="text-xl font-semibold mt-6 mb-3"><strong>1. Definition, Taxonomy &amp; Classification</strong></h2><p class="ml-4 mb-2"><strong>Brucellosis</strong> (aka Malta, Crimean, Mediterranean, Rock, undulant, Bang’s disease).Caused by <em>Brucella</em> spp.: small, <strong>Gram-negative coccobacilli</strong>, <strong>facultative intracellular pathogens</strong> (within macrophages/reticuloendothelial system).non-motile, non-spore-forming, aerobic.<em>B. abortus</em> and <em>B. suis</em> may require 5–10% CO₂.Do not ferment sugars.<strong>Closely related</strong> to <em>Bartonella</em></p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Human pathogenic species:</strong></h3><p class="ml-4 mb-2"><em>B. melitensis</em>: goats, sheep, camels – <strong>most virulent, most common worldwide</strong>, acute presentation.<em>B. abortus</em>: cattle.<em>B. suis</em>: pigs, hares, reindeer.<em>B. canis</em>: dogs (milder human disease).Rare: <em>B. ceti</em>, <em>B. pinnipedialis</em> (marine mammals), <em>B. inopinata</em> (human isolate, e.g. breast implant).</p><h2 class="text-xl font-semibold mt-6 mb-3"><strong>3. Epidemiology</strong></h2><p class="ml-4 mb-2"><strong>Worldwide zoonosis</strong>; most common zoonotic infection globally.<strong>Endemic regions</strong>: Mediterranean basin, Middle East, Africa, Latin America, Central and South Asia.UK: ~10 imported cases per year.Important occupational hazard: abattoir workers, vets, farmers, meat inspectors, lab staff.Human-to-human: rare (sexual, congenital, breast milk, transplant).<strong>Ingestion</strong>: unpasteurised dairy (milk, cheese) &gt; pasteurisation. <strong>Direct contact</strong>: animal blood, tissues, aborted products &gt; eliminated by animal vaccination).<strong>Inhalation</strong>: aerosols on farms, in labs &gt; PPERare human-to-human.Worry re: bioterrorism</p><h2 class="text-xl font-semibold mt-6 mb-3"><strong>5. Pathogenesis</strong></h2><p class="ml-4 mb-2">Enters via mucosa/skin → regional lymph nodes → bloodstream → reticuloendothelial organs.Intracellular survival: inhibits apoptosis, suppresses Th1/TNF-α responses.<strong>Virulence factors</strong>:Smooth LPS (resists complement killing).VirB type-IV secretion system (T4SS).BvrR/BvrS two-component system.Cyclic β-1,2 glucans.Superoxide dismutase and urease (acid survival).Forms granulomas in liver, spleen, marrow.Persistence in granulomas → relapsing or chronic disease.</p><h2 class="text-xl font-semibold mt-6 mb-3"><strong>6. Laboratory Diagnosis</strong></h2><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Safety</strong></h3><p class="ml-4 mb-2"><strong>Hazard Group 3</strong>. Highly infectious (10–100 organisms enough).Commonest lab-acquired infection. Work in BSL-3. Notify lab when suspected.</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Specimens</strong></h3><p class="ml-4 mb-2">Blood cultures (yield 15–70%).Bone marrow: <strong>gold standard</strong>Other: Tissue, synovial fluid, CSF</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Culture</strong></h3><p class="ml-4 mb-2">Slow-growing: 2–3 days up to 8 weeks (usually positive 7–21 days).Small convex non-haemolytic colonies.Chocolate agar, blood agar, Brucella broth.MALDI-TOF can identify (under BSL-3).Microscopy: Gram-negative coccobacilli, faint staining.Biochemical tests:  Oxidase +, catalase +, urease + (rapid).Slide agglutination with specific antisera.Molecular : PCR assays increasingly used (esp. for focal disease, FFPE tissue).Serology<strong>SAT (Standard tube agglutination test)</strong>: titre ≥1:160 significant.<strong>Rose Bengal test</strong>: screening.ELISA (IgM vs IgG).Coombs anti-Brucella: useful in chronic disease.<em>B. canis</em> requires separate serology.</p><h2 class="text-xl font-semibold mt-6 mb-3"><strong>7. Clinical Features</strong></h2><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Incubation</strong></h3><p class="ml-4 mb-2">Typically 2–4 weeks (range: 5 days – 6 months).</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>General symptoms</strong></h3><p class="ml-4 mb-2">“Great imitator”: non-specific systemic illness.<strong>Undulant fever</strong>, night sweats (malodorous, “wet hay” smell), malaise, anorexia, arthralgia, myalgia, headache, weight loss.Lymphadenopathy, hepatosplenomegaly.Anaemia, leukopenia, thrombocytopenia possible.</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Focal disease (~30%)</strong></h3><p class="ml-4 mb-2"><strong>Osteoarticular</strong> (most common, up to 50%): sacroiliitis, spondylitis, peripheral arthritis.<strong>Genitourinary</strong>: epididymo-orchitis; female pelvic infections, abortion, infertility.<strong>Hepatic</strong>: hepatitis, granulomas, abscesses.<strong>Cardiac</strong>: endocarditis (&lt;2% but major cause of death), myocarditis, pericarditis, mycotic aneurysms.<strong>Neurological (10%)</strong>: neurobrucellosis – meningitis, meningoencephalitis, myelitis, radiculopathy, cranial nerve palsy.<strong>Respiratory</strong> (rare): bronchitis, pneumonia, pleural effusion, TB-like miliary pattern.<strong>Ocular</strong>: uveitis, optic neuritis.<strong>Cutaneous</strong>: varied, vasculitic, psoriasiform lesions.<strong>Pregnancy</strong>: ↑ risk of miscarriage, preterm labour, congenital infection → avoid breastfeeding.<strong>Children</strong>: abdominal pain, arthritis more common. Chronicity rare.</p><h2 class="text-xl font-semibold mt-6 mb-3"><strong>8. Treatment</strong></h2><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Principles</strong></h3><p class="ml-4 mb-2">Always <strong>combination therapy</strong> for ≥6 weeks.Aim: intracellular penetration, relapse prevention.</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Uncomplicated brucellosis (WHO first-line)</strong></h3><p class="ml-4 mb-2"><strong>Doxycycline 100 mg PO BD × 6 weeks + Rifampicin 600–900 mg OD × 6 weeks</strong>.Alternative: Doxycycline × 6 weeks + Streptomycin (or gentamicin 5mg/kg) 1 g IM daily × 2–3 weeks.</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Complicated</strong></h3><p class="ml-4 mb-2"><strong>Spondylitis/osteomyelitis</strong>: prolonged (3–6 months).<strong>Neurobrucellosis</strong>: Doxycycline + Rifampicin + Ceftriaxone (IV 1 month) for 4–6 months. Continue until CSF normalises.<strong>Endocarditis</strong>: Doxycycline + Rifampicin + Aminoglycoside; surgery often needed.<strong>Pregnancy</strong>: Rifampicin monotherapy (TMP-SMX if appropriate, but avoid near term).<strong>Children &lt;8 years</strong>: Rifampicin + TMP-SMX.</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Special note</strong></h3><p class="ml-4 mb-2">Vaccine strain <em>B. abortus</em> RB51 is <strong>rifampicin-resistant</strong> → use doxycycline + TMP-SMX.</p><h3 class="text-lg font-semibold mt-6 mb-3"><strong>Relapse</strong></h3><p class="ml-4 mb-2">Occurs in 5–15%. Risk: poor compliance, late diagnosis, focal disease. Retreatment with prolonged combos.</p><h1 class="text-2xl font-bold mt-8 mb-4"><strong>Key Exam Pearls</strong></h1><p class="ml-4 mb-2"><strong>Bone marrow culture &gt; blood culture</strong> for sensitivity.<strong>B. melitensis</strong> = most pathogenic.<strong>Combination therapy (Doxy + Rifampicin)</strong> always.<strong>Endocarditis = main cause of mortality</strong>.<strong>Neurobrucellosis → triple therapy + prolonged duration</strong>.<strong>Lab hazard – inform lab</strong></p>
</div>